From a mechanistic perspective, the available evidence suggests that β3-AR activation might be beneficial in the early ischemic phase of ROP, as it could mitigate oxygen-induced vascular regression and preserve normal vascular maturation. The gene discussed is ADRB3; the disease is retinopathy of prematurity.